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Development and validation of LC–MS/MS method for quantitative
determination of (−)-securinine in mouse plasma
Simuli L. Wabuyele , David Wald , Yan Xu
Introduction
Securinine is a major alkaloid found in the plant leaves of
Securinega suffruticosa, a sub-tropical semi-shrub that has been
used in traditional Chinese folk medicine [1,2]. (−)-Securinine (SE)
has been reported to have a wide range of pharmacological activi-
ties such as antagonist of-GABAA receptor [3,4], therapeutic agent
for the treatment of sequela of poliomyelitis, amyotrophic lateral
sclerosis (ALS) and aplastic anemia [5,6], andmacrophage activator
against Coxiella burnetii [7], or an inhibitor of parasitic (Toxoplasma
gondii) proliferation [8].More recently, SE has been found to induce
apoptosis in various human cancer cell lines including HL-60 [9],
SW480 [10] and p53-deﬁcient colon cancer cells [11], and pro-
mote differentiation in several acute myeloid leukemia (AML) cells
lines such as HL-60, THP-1 and OCI-AMLT3, as well as cells from
primary leukemic patients [12]. Furthermore, SE has been demon-
strated to synergizewith other differentiation agents (e.g., all-trans
retinoic acid, decitabine, and 1,25-dihydroxyvitaminD3)which are
currently used for treatment of AML; hence, SE could be used to
enhance the clinical activity and reduce the toxicity of these agents
[12].
To support the preclinical and clinical studies of SE, a quanti-
tative analytical method is critically needed for the measurement
of the compound in biological specimens. Based on a recent Sci-
ﬁnder® scholar database search, the current analytical methods for
SE analysis are mainly qualitative, which include HPLC-UV [13,14],
and CE-UV [15]. The only quantitative assay reported for SE is a
GC–MS method which lacks adequate sensitivity for analysis of
biological samples and has not been validated [16].
In this work, an LC–MS/MS method for quantitative determi-
nation of SE in mouse plasma has been developed. Norsecurinine
(norSE)wasused as the internal standard (IS). A salting-out assisted
liquid–liquid extraction (SALLE) procedure was implemented for
plasma sample extraction. Separation of SE and IS was carried
out on a reverse-phase column and quantiﬁcation was achieved
by positive electrospray ionization tandem mass spectrometry
(ESI+–MS/MS) in multiple-reaction monitoring mode (MRM). The
LC–MS/MS method developed for SE analysis has been validated in
mouse plasma according to the guidance for industry on bioanalyt-
ical method validation by the US Food and Drug Administration
(US-FDA) [17] and the white paper of the 2006 bioanalytical
019
method validation workshop [18,19], and applied to the measure-
ment of SE in mouse plasma samples from an animal study.
Experimental
Chemicals and solutions
(−)-Securinine or SE (C13H15NO2, CAS Registry Number: 5610-
40-2) was obtained from LKT Laboratories (St. Paul, MN, USA).
(+)-Norsecurinine or norSE (C12H13NO2, CAS Registry Number:
25472-13-3) was from Ryan Scientiﬁc (Mount Pleasant, SC, USA).
Ammonium acetate and dimethyl sulfoxide (DMSO) were from
Sigma–Aldrich (St. Louis, MO, USA). HPLC-grade acetonitrile was
from Pharmco-AAPER (Shelbyville, KY, USA). Six pooled blank
mouse plasmas (Na citrated) with speciﬁed lot numbers (1H1453-
02, 1R11-0823a, 1R11-0823b, 1H1453-01, 1R11-MS-Nac-0811 and
1R10-NSA-02) were purchased from Innovative Research (Novi,
MI, USA). Deionized water was obtained from an in-house Barn-
stead NANOpureTM water puriﬁcation system (Thermo Scientiﬁc,
Waltham, MA, USA) with a resistance reading of 18.2M.
Stock standard solutions of SE (2.00mgmL−1) and norSE
(1.20mgmL−1) were prepared individually by dissolving proper
amount of each accurately weighed compound in a known volume
of DMSO. Aliquots (20.0L) of the each stock solution were stored
at −80 ◦C prior to use. SE working standard solutions (12.0, 24.0,
36.0, 120, 240, 360, 1.20×103, 2.40×103, 1.08×104, 1.20×104
and 3.60×104 ngmL−1) were prepared daily by serial dilution of
the stock standard solution of SE with DMSO. Working IS solution
(1.20×103 ngmL−1) was prepared by three sequential dilutions
(1/10) of the stock IS solution in DMSO.
Ammonium acetate solutions (0.100M and 2.00M) were pre-
paredbydissolvingappropriate amountsof thebuffer salt in known
volumes of water. 10.0mM ammonium acetate (pH 6.8) was pre-
pared by a 1/10 dilution of the 0.100M solution with water. The
chromatographic mobile phase consisting of 40% acetonitrile and
60% 10.0mM ammonium acetate was prepared by mixing 200mL
of acetonitrile with 300mL of 10.0mM ammonium acetate.
Preparation of plasma calibrators and quality controls (QCs)
SE plasma calibrators (0.600, 1.20, 6.00, 12.0, 60.0, 120 and
600ngmL−1), QCs (1.80, 18.0, 540ngmL−1) and dilution QC
(1.80×103 ngmL−1) were prepared by diluting every 50.0L
of the aforementioned SE working standard solutions with
950L of pooled blank mouse plasma. SE plasma zero calibra-
tor (0.000ngmL−1) was prepared by diluting 50.0L of DMSO
with 950L of pooled blank mouse plasma. Aliquots (100.0L)
of plasma calibrators, QCs and dilution QC were kept in 1.50mL
microcentrifuge tubes (VWR, Radnor, PA, USA) and stored at−80 ◦C
before use.
Preparation of plasma samples
Plasma calibrators, QCs, dilutionQC and themouse plasma sam-
ples from animal study (see Section 2.9) were thawed at room
temperature. Prior to the sample extraction by SALLE, the mouse
plasma samples anddilutionQCwere subjected to 10-timedilution
using pooled blank mouse plasma, then 5.00L of the working IS
solution (1.20×103 ngmL−1) was added to each 100L of plasma
sample except the double blankwhere 5.00L of DMSOwas added.
After vortexmixing, 600L of cold acetonitrile (−20 ◦C) and 100L
of 2.00M ammonium acetate were added sequentially to each
plasma sample. The resultant mixture was vortexed for 3 s, and
then centrifuged at 15,000× g and 4 ◦C for 10min. After centrifuga-
tion, 200L aliquot of supernatant was diluted 1:1 with 10.0mM
ammonium acetate (pH 6.8) and used directly for LC–MS/MS anal-
ysis.
LC–MS/MS system
The LC–MS/MS instrumentation used for this work consisted
of a Shimadzu Prominence UFLC system (Shimadzu, Columbia,
MD, USA) and an AB Sciex QTrap 5500 mass spectrometer
(AB Sciex, Foster City, CA, USA). The UFLC system included a
system controller (CBM-20A), two binary pumps (LC-20AD), a
temperature-controlled autosampler (SIL 20AHT) and an online
degasser (DGU20A3), and themass spectrometer camewithaTurbo
IonSpray source. TheUFLC systemoutletwas connected to themass
spectrometer via high-pressure polyether ether ketone (PEEK) tub-
ing (0.0625 in. o.d.×0.0100 in. i.d.).
Chromatographic separation
The chromatographic separation was carried out isocratically
under ambient temperature on a reverse-phase Gemini Nx C18
(2.1mm i.d×150mm, 5m, 110 A˚) column (Phenomenex, Tor-
rance, CA, USA) with an inline VHP ﬁlter (0.5m, stainless steel)
fromUpchurch Scientiﬁc (OakHarbor,WA, USA). The sample injec-
tion volume was 10.0L and the mobile phase ﬂow rate was
0.200mLmin−1. Prior to sample analysis, the column was ﬁrst
equilibrated with at least 20 column volumes of the mobile phase
at a ﬂow rate of 0.200mLmin−1.
Mass spectrometric detection
AB Sciex QTrap 5500 tandem mass spectrometer was operated
in positive electrospray ionization (ESI+) mode. It was tuned by
ﬂow injection analysis of SE (250ngmL−1) andnorSE (500ngmL−1)
in the mobile phase for both compound-dependent and source-
dependent parameters. The optimized ionization parameters were
as follows: curtain (CUR), 20psi; collision-activated dissociation
(CAD) gas, medium; nebulizer gas (GS1), 40psi; turbo heater gas
(GS2), 25psi; ion spray voltage (IS), 5500V; source temperature
(TEM), 300 ◦C. High purity nitrogen (99.99%) was used as the
nebulizer, auxiliary, collision and curtain gases. The declustering
potential (DP), entrance potential (EP), collision energy (CE) and
collision cell exit potential (CXP)were set at 65, 6.0, 30 and 8.0V for
SE and 80, 7.0, 35, 6.0V for norSE. Quantiﬁcationwas performed by
multiple-reaction-monitoring (MRM) mode with mass transitions
m/z 218.1→84.1 for SE, and m/z 204.1→70.2 for norSE. The dwell
time for each transition was 300ms and the mass resolutions (Q1
and Q3) were set at unit.
Data acquisition and analysis
Data acquisition and peak integration were carried out by the
AB Sciex Analyst® software (version 1.5.2). The linear regression
calibration equation was obtained by plotting the mean-peak-area
ratios of SE plasma calibrators to those of the IS versus the concen-
trations of SE calibrators using a weighting factor of 1/x (where x is
the nominal concentration of a plasma calibrator).
Stability study
The stability of SE was investigated using the SE stock solu-
tions (2.00mgmL−1), low and high plasma QC samples (1.80,
540ngmL−1), and the stability of norSE was also determined sepa-
rately using the norSE stock solution (1.20mgmL−1) and a plasma
sample at a concentration of 60.0ngmL−1. In the latter studies, SE
was used as the IS for norSE.
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Stabilities of stock solution and mouse plasma samples were
assessed by short-term (6 and 24 h) standing on bench-top at 23 ◦C
and in the auto sampler at 4 ◦C (post preparative); freeze-and-thaw
cycles; and long- term storage at −20 and −80 ◦C. The stabilities of
SE and norSE were determined by comparing the mean-peak-area
ratios of analyte to the IS in the test sample to those of freshly
prepared samples, and expressed as percentages.
Animal study
The  LC–MS/MS method developed was applied to the measure-
ment of SE concentrations in the following animal study which
had been approved by the Case Western Reserve University Insti-
tutional Animal Care and Use Committee (IACUC). BALB/c mice
were obtained from Jackson laboratories (Bar Harbor, ME,  USA).
The mice were randomly housed, and had an average body weight
of 25 g at the time of SE injections. The injectable SE (1 mg  mL−1)
was prepared in 10% DMSO aqueous solution which was  given to
mice as a single-bolus intraperitoneal (i.p.) injection at a dose of
4.00 mg  kg−1. The mouse blood samples were collected via ocular
puncture into 1.5 mL  microcentrifuge tubes containing heparin as
anti-coagulant at the following time points: 0 (pre-dose), 1.5, 3,
7, 9, 15, 30 and 120 min. For the pre-dose sample, the mouse was
injected with only 10% DMSO aqueous solution without SE. One
whole blood sample (ca. 100 L) was drawn from single mouse at
each time point, which was placed in ice immediately. The whole
blood samples were processed within 15 min  of collection by cen-
trifugation at 1000 × g and 4 ◦C for 10 min. The harvested plasma
samples (ca. 50 L each) were stored at −80 ◦C until analysis.
Results and discussion
Internal  standard (IS)
Structural analog of SE was used as IS since stable heavy iso-
tope of SE was  not available. Initially, several custom-synthesized
SE  analogs were tested; however, most of the analogs chosen
contained trace amount of SE due to the use of SE as precur-
sor in synthetic routes. NorSE was  eventually chosen since it was
free of SE. NorSE is structurally similar to SE, but differs only by
one CH2 unit, which has a pyrrolidinly instead of piperidinyl
ring.
Analyte solubility
According  to the Sci-Finder® Scholar database search, the log P
values of SE and norSE are −0.969 and −1.497 respectively. These
compounds should be hydrophilic rather than hydrophobic. How-
ever, we found them to be difﬁcult to dissolve in either aqueous
solution or plasma directly, which is probably attributed to their
large rigid ring structures. Although ethanol can dissolve these
compounds, it can cause protein precipitation in plasma, result-
ing in poor analytical reproducibility. The suitable solvent to
dissolve both SE and norSE is DMSO. In this work, the SE and
norSE working standard solutions were prepared in 100% DMSO,
which was diluted to ≤10% DMSO in plasma calibrators and QC
samples to ensure no protein precipitation from plasma matrices
[20].
Fig. 1. The mass spectra of the precursor and product ions of SE and norSE (IS). (A) The molecular ion of SE; (B) the major fragment of SE; (C) the molecular ion of the IS; and
(D)  the major fragment of the IS.
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Mass spectrometric detection
Due to the chemical structures of SE and norSE (IS), they are
more readily to acquire protons than lose one in electrospray ion-
ization. Hence, the positive electrospray ionization mode was used
in this work. As shown in Fig. 1A and C (full scan spectra), SE and
norSE produced protonated molecular ions [M+H]+ at m/z 218.1
and m/z 204.1, respectively. These molecular ions produced major
fragments (Fig. 1B and D) at m/z 84.1 and m/z 70.2, respectively.
Therefore, the mass transitions of m/z 218.1 → 84.1 for SE and m/z
204.1 → 70.2 for the IS were chosen for the MRM  quantiﬁcation. The
assignments of the SE and norSE fragments in Fig. 1 were initially
done by ACD/MS Fragmenter software (ACD Labs Toronto, Canada),
and further conﬁrmed by the experimental data.
Chromatographic separation
In this work, reverse-phase liquid chromatography (RP–LC)
columns such as Waters Xterra® RP-18 and Phenomnex Gemini
Nx C18 (Phenomnex, Torrance, California) columns were tested for
separation of SE and norSE. Either one was suitable for the work.
Since the Gemini Nx C18 gave higher signal intensity, it was chosen
for this method.
The  composition of the mobile phase used for separation was
optimized. Acetonitrile was chosen as the organic solvent due to
its greater solvent strength and higher signal response of analytes
in mass spectrometry than those of methanol; and ammonium
acetate (10.0 mM)  was used as the buffer because it suppressed the
formation of sodium ion adducts and reduced peak tailing. Since
the pH value of a mobile phase can inﬂuence the retention of amine
derivatives on reverse phase column, the optimal pH of the mobile
phase was investigated. In this work, baseline resolution of SE and
norSE was achieved with ammonium acetate (10.0 mM)  at pH 6.8.
Under this pH value, both SE (pKa = 8.29) and norSE (pKa = 8.78)
were in their protonated forms.
The  percent content of acetonitrile in the mobile phase was
also investigated. Initially 70% acetonitrile was used; although it
produced shorter retention times for the analytes, it caused co-
elution of an endogenous lipid (2.7 min) with SE (3.2 min) in plasma
sample, and resulted in signiﬁcant ion suppression to SE (Fig. 2A).
The lipid co-eluted was  identiﬁed to be 1-stearyl-rac-1-glycerol
(monoacylglycerol) [21]. To circumvent this problem, the percent
content of acetonitrile was reduced to 40% by which no apparent
1-stearyl-rac-1-glycerol was  observed near the retention time of
SE (Fig. 2B).
For  the LC–MS/MS method developed, the optimized mobile
phase composition consisted of 40% acetonitrile and 60% 10.0 mM
ammonium acetate (pH 6.8). Using this mobile phase, separation of
SE and norSE could be achieved on the Gemini Nx C18 with retention
times of 2.6 min  and 5.5 min  for norSE and SE, respectively (Fig. 3).
Preparation of plasma samples
In this work, liquid–liquid extraction (LLE) was  ﬁrst examined
for sample preparation. In detail, 100 L of plasma sample was  ﬁrst
diluted with 0.05% ammonium aqueous solution to deprotonate
the analytes, then 1.00 mL  of ethyl acetate was added. The organic
layer was transferred into borosilicate glass tubes (12 mm × 75 mm,
VWR) and dried under nitrogen (10 psi) by TurboVap LV evaporator
(Zymark, Hopkinton, MA,  USA) at 40 ◦C for 30 min, and reconsti-
tuted in the mobile phase for analysis. Due to the high volatilities
of SE and norSE, cross-vial contamination was  observed. Further-
more, the recoveries of analytes were low and the matrix effect was
high by LLE. To overcome these problems, a salting-out assisted
liquid–liquid extraction (SALLE) protocol was later adopted for
plasma sample preparation [22,23], where a concentrated volatile
salt (i.e., 2.00 M ammonium acetate) with a cold organic solvent
(i.e., acetonitrile) were added to promote protein precipitation
and induce phase separation. The analytes extracted were deter-
mined by LC–MS/MS after a direct dilution of the organic phase
Fig. 2. The effect of the percent organic additive in the mobile phase on the separation of SE from lipid interference. (A) 70% ACN and 30% buffer (10.0 mM ammonium acetate
pH  6.8) (B) 40% ACN and 60% buffer (10.0 mM ammonium acetate pH 6.8). Top chromatograms show the MRM  mass transitions of SE, and the bottom chromatograms show
the  MRM  mass transitions of 1-stearyl-rac-1-glycerol (monoacyl glycerol).
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Fig. 3. The representative mass chromatograms of SE and the IS in mouse plasma:
(A)  double blank plasma (with neither SE nor IS); (B) single blank plasma (with IS
only, 60 ng mL−1); and (C) at LLOQ (0.600 ng mL−1; IS, 60 ng mL−1).
with 10.0 mM  ammonium acetate (pH 6.8) buffer (at 1:1 ratio). The
SALLE protocol was found to be effective in removal of matrix inter-
ference and producing good analyte recoveries (see data in Sections
3.6.2 and 3.6.3).
Method validation
The  method developed was validated in mouse plasma accord-
ing to the US-FDA guidance for industry on bioanalytical method
validation [17] and the white paper of the 2006 bioanalytical
method validation workshop [18,19] in terms of selectivity, lower
limit of quantitation, linear response range, recovery, matrix effect,
accuracy and precision, as well as stability for both short-term sam-
ple processing and long-term sample storage.
Selectivity and lower limit of quantitation (LLOQ)
The  selectivity of the method was evaluated by comparing the
mass chromatograms of six lots of blank plasma samples with those
of the spiked plasma calibrator at the LLOQ. In this work, there were
no endogenous interference observed at the retention times and
mass transitions of SE and the IS (Fig. 3A). Furthermore, there was
Table 1
Accuracy and precision of SE at LLOQ in six individual lots of mouse plasma (n = 5).
Plasma
matrix
Nominal
[SE]
(ng mL−1)
Mean
measured [SE]
(ng  mL−1)
SD (ng mL−1) %RE %CV
Lot 1 0.600 0.61 0.02 2 3
Lot 2 0.600 0.58 0.03 −3 5
Lot 3 0.600 0.57 0.01 −5 2
Lot 4 0.600 0.61 0.02 2 3
Lot 5 0.600 0.56 0.02 −7 4
Lot 6 0.600 0.56 0.03 −7 5
Each datum point was  calculated by ﬁve replicate measurements.
%RE  = [(measured − nominal)/(nominal)] × 100%; %CV = (SD/mean) × 100%.
no interference from the IS at the retention time and m/z for SE
(Fig. 3B).
The  LLOQ of the method was deﬁned by the lowest calibrator of
the calibration curve (0.600 ng mL−1) (Fig. 3C). As shown in Table 1,
the accuracy expressed as percent error (%RE) and precision as cor-
relation of variation (%CV) were ≤±7% and ≤5% respectively, based
on ﬁve replicate measurements in six lots of blank plasma matri-
ces. Since the acceptable accuracy (%RE) and precision (%CV) were
≤±20% and 20%, these results imply that the actual LLOQ of the
method may  be lower than 0.600 ng mL−1.
Matrix  effect
The  sample matrix effect was assessed by the matrix factor (MF)
in six lots of mouse plasmas. The absolute MFs  of SE and the IS
were determined by comparing the mean-peak-area of SE and the
IS in the spiked plasma matrix after SALLE (n = 5) with those of SE
and the IS in the mobile phase at low- and high-QCs (1.80 and
540 ng mL−1). The IS normalized MF  was  determined by MFs  of
SE over those of the IS. As shown in Table 2, the absolute MFs  of
SE and the IS ranged from 0.99 to 1.15 and 1.01 to 1.10 respec-
tively. The IS normalized MFs  were in the range of 0.92–1.07. These
results indicate that the plasma matrix effect was negligible in this
method.
Analyte recovery by SALLE
The absolute recoveries of SE and the IS were determined by
comparing the mean-peak-area of SE and the IS in the corre-
sponding QC plasma samples (n = 5) at low-, mid- and high-QC
concentrations (1.80, 18.0, 540 ng mL−1) with those of SE and the
IS in the spiked in plasma matrix after SALLE. The IS normalized
recoveries were determined by the recoveries of SE over those of
the IS. As shown in Table 3, the mean absolute recoveries for SE and
the IS ranged 79–86% and 79–80%, respectively; and the mean IS
normalized recoveries ranged 99–109%.
Carryover
The carryover of the analytes was assessed with ﬁve batches
of validation calibrators by injecting pooled blank plasma (no SE
and the IS) immediately after the injection of the plasma calibrator
at the highest concentration (600 ng mL−1). There were no analyte
peaks observed using 90% acetonitrile as the injector needle wash-
ing solution. Hence, sample carryover was not a problem in this
method.
Accuracy and precision
The intra-run accuracy and precision were determined by ﬁve
replicate measurements of each low-, mid- and high- QC  samples
(1.80, 18.0, 540 ng mL−1) as well as dilution QC (1.80 × 103 ng mL−1)
in the same validation batch. The inter-run accuracy and precision
were determined by ﬁve parallel measurements of ﬁve identical
sets of each QC samples over ﬁve different validation batches.
As shown in Table 4, the intra-run accuracy and precisions of all
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Table 2
Matrix effect on SE in six individual lots of mouse plasma (n = 5).
Plasma matrix [SE] (ng mL−1) MFSE ± SDa MFIS ± SDb IS normalized MF  ± SDc
Lot 1 1.80 1.03 ± 0.02 1.04 ± 0.04 0.98 ± 0.03
540  1.05 ± 0.05 1.09 ± 0.05 0.96 ± 0.03
Lot 2 1.80 1.02 ± 0.03 1.04 ± 0.02 0.98 ± 0.02
540  1.01 ± 0.05 1.10 ± 0.06 0.92 ± 0.04
Lot 3 1.80 1.03 ± 0.03 1.03 ± 0.04 0.99 ± 0.02
540  1.03 ± 0.03 1.03 ± 0.04 0.99 ± 0.02
Lot 4 1.80 1.05 ± 0.03 1.05 ± 0.03 1.01 ± 0.02
540  0.99 ± 0.06 1.06 ± 0.03 0.93 ± 0.07
Lot 5 1.80 1.01 ± 0.01 1.09 ± 0.02 0.92 ± 0.02
540  1.02 ± 0.01 1.01 ± 0.08 1.01 ± 0.09
Lot 6 1.80 1.15 ± 0.04 1.08 ± 0.02 1.07 ± 0.04
540  1.02 ± 0.01 1.02 ± 0.06 1.00 ± 0.05
a MFSE = (mean peak area of SE in extracted plasma matrix)/(mean peak area of SE in mobile phase).
b MFIS = (mean peak area of the IS in extracted plasma matrix)/(mean peak area of the IS in mobile phase).
c IS normalized MF  = MFSE/MFIS.
Table 3
Recovery of SE in pooled mouse plasma (n = 5).
[SE] (ng mL−1) RecoverySE ± SD
(%)
RecoveryIS ± SD
(%)
IS normalized
Recovery ± SD (%)
1.80 86 ± 3 79 ± 2 109 ± 2
18.0 84 ± 3 79 ± 1 107 ± 3
540 79 ± 2 80  ± 3 99  ± 2
PA = mean peak area.
Recovery of SE = (PA of SE in plasma matrix/PA of SE in extracted plasma
matrix)  × 100%.
Recovery of IS = (PA of IS in plasma matrix/PA of IS in extracted plasma
matrix)  × 100%.
IS normalized recovery = (recovery of SE/recovery of the IS) × 100%.
Table 4
Intra- and inter-run accuracy and precision of SE in pooled mouse plasma (n = 5).
Nominal [SE]
(ng  mL−1)
Measured [SE]
(ng  mL−1)
SD (ng mL−1) %RE %CV
Intra-runa
1.80 1.8 0.1 0.0 6
18.0 17.0 0.5 −6 3
540 545 6 1 1
1.80 × 103c 1.75 × 103 8 × 101 −3 5
Inter-runb
1.80 1.7 0.1 −6 6
18.0 17.0 0.4 −6 2
540 549 8 2 1
1.80 × 103c 1.91 × 103 7 × 101 6 4
a Determined by ﬁve replicate measurements of each QC sample within a vali-
dation batch.
b Determined by ﬁve parallel measurements of ﬁve identical QC samples at each
concentration over ﬁve validation batches.
c The dilution QC was measured after 10 times dilution with the pooled blank
plasma.
Table 5
Accuracy and precision of SE plasma calibrators over ﬁve validation batches.
Nominal [SE]
(ng  mL−1)
Measured [SE]
(ng  mL−1)
SD
(ng  mL−1)
%RE  %CV
0.600 0.59 0.02 −2 3
1.20 1.20 0.06 0.0 5
6.00 6.00 0.3 0.0 5
12.0 11.9 0.7  −1 6
60.0 62.0 4.0 3 6
120 120 5 0.0 4
600 597 7 −0.5 1
Fig. 4. The representative mass chromatograms of animal study. (A) Predosed
mouse  plasma (run with 60 ng mL−1 IS); (B) plasma sample collected at 3 min  after
i.p.  injection (run with 60 ng mL−1 IS); and (C) plasma sample collected 30 min  after
i.p. injection (run with 60 ng mL−1 IS).
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the QCs samples were ≤±6% and ≤6%, and the inter-run accu-
racy and precisionswere ≤±6% and ≤6% respectively. These results
indicate that the method developed has adequate accuracy and
precision.
Linearity
The calibration curve of SE in mouse plasma was constructed
using a double blank (with neither SE nor IS), a single blank
(zero calibrator, with IS) and seven non-zero SE plasma cali-
brators (0.600, 1.20, 6.00, 12.0, 60.0,120 and 600ngmL−1), with
the concentration of the IS at 60.0ngmL−1. The mean-peak-area
ratios of SE to those of IS were plotted against the nominal
concentration of SE. The calibration equation derived from ﬁve
validation batches using 1/x weighted least-square linear regres-
sion was Y=0.135 (±0.009)x+0.009 (±0.008). A linear range of
over three orders of magnitude (0.600–600ngmL−1) was obtained
with a correlation coefﬁcient of 1.00, and the accuracy and
precision of plasma calibrators were ≤±3 and ≤6, respectively
(Table 5).
Stability study
The stabilities of SE and norSE under various storage conditions
were assessed. As shown in Table 6, the recoveries for SE stock solu-
tion (23 ◦C) were 100% and 103% at 6h and 24h, and 105% by long
term storage (−80 ◦C, 5 months). The recoveries for SE plasma QCs
were 94–101% on bench-top (23 ◦C) and 100–104% in auto sam-
pler (4 ◦C) within 24h. The recoveries of SE plasma QCs by three
freeze-and-thaw cycles (−20 to 23 ◦C) and long-term storage at
−80 ◦C (30 days) were 97–99% and 97–99%, respectively. However,
it should be noted that the recoveries of SE plasmaQCs by long term
storage at −20 ◦C for 30 days were rather low (76–79%). Therefore,
plasma samples should be kept at −80 ◦C for long term storage, and
plasma samples should be analyzed within 24h timeframe after
thawing.
Table 6
Stability of SE and the IS in mouse plasma samples under various conditions.
Test conditions Temperature (◦C) SEa Recovery± SD (%) (n=3)
6h 24h
Bench-top 23 Stock solution 100 ± 1 103 ± 1
Freezer (5 months) −80 Stock solution 105 ± 2
Bench-top 23 Low QC 100 ± 2 96 ± 4
High QC 101 ± 5 94 ± 3
Autosampler 4 Low QC 100 ± 2 104 ± 7
High QC 100 ± 3 103 ± 3
3 Freeze–thaw cycles −20 to 23 Low QC 97 ± 2
High QC 99 ± 4
Long-term (30 days) −20 Low QC 76 ± 3
High QC 79 ± 3
Long-term (30 days) −80 Low QC 99 ± 3
High QC 97 ± 3
Test conditions Temperature (◦C) NorSEb Recovery± SD (%) (n=3)
6h 24h
Bench-top 23 Stock solution 104 ± 5 101 ± 5
Bench-top 23 Plasma sample 102 ± 6 103 ± 3
Autosampler 4 Plasma sample 101 ± 7 105 ± 4
3 freeze–thaw cycles −20 to 23 Plasma sample 96 ± 5
a The concentration of SE stock solution was 2.00mgmL−1 which was measured by serial dilution to 1.80ngmL−1 in mobile phase. The concentrations of SE in the low and
high QCs were 1.80 and 540ngmL−1, respectively.
b The concentration of norSE stock solution was 1.20mgmL−1 which was measured by serial dilution to 60.0ngmL−1 in mobile phase. The norSE plasma sample was at a
concentration of 60.0ngmL−1.
Fig. 5. Themeanconcentration-timeproﬁleof SE inmouseplasma(n=3)after single
i.p. bolus injection at the dose of 4mgkg−1.
The recoveries of norSE under various conditions were in the
range of 96–105%, which indicated that no signiﬁcant loss of norSE
was observed under the experimental conditions.
Method application
The validated LC–MS/MS method was applied to the measure-
ment of plasma concentrations of SE in BALB/C mice. The animal
sampleswere collected and analyzed by the procedure described in
the experimental section. The representativemass chromatograms
of SE in mouse plasma from the animal study are shown in Fig. 4.
The concentration of SE in each mouse sample was back calcu-
lated using the peak-area ratio of SE to that of the IS from the
calibration equation with the proper dilution factor. Fig. 5 shows
the mean SE plasma concentration-time proﬁle in mice (n=3)
after a single bolus i.p. injection of 4mgkg−1 SE, which demon-
strated theapplicabilityof themethod forpharmacokinetic study in
mice.
025
Conclusions
An LC–MS/MS method for quantitative determination of SE in
mouse plasma has been developed and validated. The method
uses SALLE procedure for sample preparation, reverse phase-liquid
chromatography for separation, and tandemmass spectrometry for
detection. Themethodhasgoodanalyte selectivity,wide linear cali-
bration range, and high accuracy and precisions. It has been applied
to the measurement of SE in mouse plasma samples; therefore,
maybe be useful for the pharmacological study of SE in mice.
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